A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Abroad (travel likely)RecruitingPHASE3

Conditions

Non-alcoholic Fatty Liver Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • GSK Clinical Trials

    Study Director

    GlaxoSmithKline